翻修腰椎融合患者尽管术后早期阿片类药物使用相似,但长期阿片类和加巴喷丁类药物需求更高
这项回顾性队列研究分析了2018-2023年间1,938例择期1-3节段腰椎融合患者(1,498例初次,440例翻修),比较两组阿片类和非阿片类镇痛药使用。翻修患者术前阿片类MME负担更高,术后30天使用率相似,但90天、1年、2年MME更高,加巴喷丁类使用从90天起更高;多变量分析确认翻修状态是1年和2年更高MME使用的独立危险因素。
要点
- 翻修患者术前阿片类MME负担显著高于初次融合患者。
- 术后30天阿片类使用率相似,但翻修患者90天至2年MME更高。
- 翻修状态是1年和2年更高MME使用的独立危险因素。
核心结论
- 翻修腰椎融合患者表现出更高的术前和术后阿片类负担以及更高的术后加巴喷丁类药物负担。
- 多变量分析确认翻修状态是1年起长期更高MME使用的独立危险因素。
- 这些发现提示翻修患者可能存在复杂的、神经病理性疼痛表型,需要量身定制的围手术期咨询和一致的长期多学科疼痛管理。
研究设计与样本
- 回顾性队列研究,纳入2018-2023年间接受择期1-3节段腰椎融合术的患者,共1,938例(1,498例初次融合,440例翻修融合)。
- 从州处方药监测计划(PDMP)提取术后30天、90天、1年和2年的阿片类和非阿片类处方数据。
- 采用双变量和多变量分析比较初次与翻修融合队列。
主要发现
- 翻修患者术前阿片类吗啡毫克当量(MME)负担更高(953 vs. 334,P<0.001)。
- 术后30天内阿片类使用率相似,但翻修患者在90天(428 vs. 219,P<0.001)、1年(1,142 vs. 382,P<0.001)和2年(1,550 vs. 497,P<0.001)MME使用更高。
- 加巴喷丁类药物使用从90天起在翻修患者中更高(19.3% vs. 13.4%,P=0.003)。
- 多变量回归确认术前MME是长期阿片类负担的最强危险因素。
- 翻修状态与1年(β=348.3,P=0.011)和2年(β=964.4,P<0.001)更高MME使用独立相关,但与90天无关。
临床怎么用
- 对翻修腰椎融合患者应进行量身定制的围手术期咨询,关注长期阿片类和加巴喷丁类药物使用风险。
- 翻修患者可能需要一致的长期多学科疼痛管理,特别是针对可能的神经病理性疼痛表型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Retrospective Cohort. OBJECTIVE: This study aimed to: (1) compare opioid use between primary and revision fusion patients; (2) evaluate differences in non-opioid analgesic use; and (3) identify risk factors of long-term opioid consumption. SUMMARY OF BACKGROUND DATA: Preoperative opioid exposure and revision surgery are recognized risk factors for prolonged postoperative opioid use after lumbar fusion, yet long-term data remain limited. METHODS: Patients who underwent elective 1-3 level lumbar spine fusion between were retrospectively identified and chart reviewed (2018-2023). Opioid and non-opioid prescription data was extracted from the state prescription drug monitoring program (PDMP) at 30 days, 90 days, 1 year, and 2 years. Patients were stratified into primary versus revision fusion cohorts and compared using bivariate and multivariable analyses. RESULTS: A total of 1,938 patients were analyzed (1,498 primary, 440 revision). Revision patients had greater preoperative opioid morphine milligram equivalent (MME) burden (953 vs. 334, P<0.001). Postoperatively, opioid use rates were similar through 30 days, but revision patients demonstrated higher MME use at 90 days (428 vs. 219, P<0.001), 1 year (1,142 vs. 382, P<0.001), and 2 years (1,550 vs. 497, P<0.001). Gabapentinoid use was also higher in revision patients beginning at 90 days (19.3% vs. 13.4%, P=0.003). Multivariable regression confirmed preoperative MME as the strongest risk factor of long-term opioid burden. Revision status was independently associated with higher MME use at 1 year (β=348.3, P=0.011) and 2 years (β=964.4, P<0.001), but not at 90 days. CONCLUSIONS: Revision lumbar fusion patients demonstrate a greater pre- and postoperative opioid burden, and a greater postoperative gabapentinoid burden. Multivariable analysis confirms revision status as an independent risk factor of greater long-term MME use, beginning at 1 year. Together these findings suggest a complex, possibly neuropathic pain phenotype in revision patients, underscoring the need for tailored perioperative counseling and consistent long-term, multidisciplinary pain management.
引用
- Olson J, Green WA, Dalton J, et al. Revision Lumbar Fusion Patients Exhibit Higher Long-Term Opioid and Gabapentinoid Needs Despite Similar Early Postoperative Use. Spine (Phila Pa 1976). 2026. PMID: 41774932. doi:10.1097/BRS.0000000000005678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。